FreePeptideCalc

GLOW Peptide Dosage Calculator (Blend)

A vendor-defined GHK-Cu, BPC-157 and TB-500 blend with no standard formula, no clinical trial of the combination and no published human dose.

Written by , who builds and maintains this site and is not a clinician. Every figure links to its primary source.

Not approved

Not approved; GLOW is a vendor-defined blend

GLOW is a marketing name rather than a recognized drug or standardized formulation. No FDA-approved product uses the name, and no monograph fixes its ingredients or ratio. Its usual components are sold separately as unapproved peptides; combining them does not create an approved product or an established dose.

No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.

Anti-doping: Contains prohibited substances. BPC-157 falls under WADA class S0 and thymosin beta-4 under class S2.

Calculator inputs

Describe the blend

Target one component; the result shows everything delivered in that same draw.

GHK-Cumg
BPC-157mg
TB-500mg

50/10/10 is an illustrative commercial fill, not a standard. Replace every value with the amount on your own label.

One draw of
3units(0.03 mL)
3 units01020304050U-100 barrel · 50 units · read the leading edge of the black plunger seal
Draw to 3 units on a 50-unit U-100 syringe.

That single draw delivers

ComponentConcentrationPer injection
GHK-Cutargeted16.67 mg/mL500 mcg
BPC-1573.33 mg/mL100 mcg
TB-5003.33 mg/mL100 mcg
Components in a blend are fixed in ratio. Changing the dose of one changes all the others by the same proportion.

Key facts

Half-life
Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
Also sold as
GLOW stack, GHK-Cu + BPC-157 + TB-500

Published doses

None. No study has published a dose for GLOW peptide blend that can be responsibly reproduced. That is a finding, not an omission — every dose figure you see for it elsewhere online comes from community convention rather than a source.

How good is the evidence?

No published paper or registered trial has tested the GLOW combination. GHK-Cu has laboratory and topical skin literature, BPC-157 is supported mostly by animal work, and the human thymosin beta-4 studies used other formulations and routes. None establishes an injectable fixed-ratio blend.

Why there is no standard GLOW peptide dosage

A dose needs a defined product before it can be studied. GLOW has neither: sellers use the same name for vials with different totals and ratios, and some add a fourth ingredient. That makes a bare instruction such as “take 10 units” meaningless twice over — a unit is only a volume, and the contents of that volume differ between vials.

The calculator therefore starts from three separate masses and reports all three components in the same draw. It does not select a target dose. Any GLOW dosing chart that gives one schedule for every vial is silently assuming both a formulation and a dose that no regulator or clinical trial has established.

What one draw of a GLOW blend contains

At the illustrative 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 fill, the ratio is 5:1:1. Every draw therefore carries five times as much GHK-Cu as either of the other components by mass. Adding more water makes the draw larger but cannot change that ratio.

This is the useful, defensible part of a GLOW calculator: it exposes the fixed-ratio constraint. If you target one component, the amounts of the other two follow automatically. Separate vials are the only way to vary them independently.

The evidence belongs to the ingredients, not the blend

The best-known GHK-Cu review discusses skin regeneration pathways and laboratory findings, not a three-peptide injectable product. Published BPC-157 evidence is dominated by animal studies, while human thymosin beta-4 research used intravenous, topical or ophthalmic preparations rather than the TB-500 fragment sold in peptide vials.

Those separate literatures cannot be added together to predict the safety, stability or effect of a premixed vial. No compatibility study shows that the three remain intact together after reconstitution, and no human trial supplies a GLOW dose, cycle or injection schedule.

Common questions

Sources

Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.

  1. RegulatorFDA· 2026-05-14
    Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
  2. RegulatorFDA
    Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
  3. RegulatorFDA· 2026-07
    July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
  4. RegulatorFDA
    Compounding Risk Alerts
  5. RegulatorWorld Anti-Doping Agency· 2026
    WADA 2026 Prohibited List
  6. RegulatorUSADA
    BPC-157 is a Prohibited Peptide
  7. Published studyBioMed Research International 2015;2015:648108· 2015-07-07
    Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration (authors declare affiliation with Skin Biology, a copper-peptide manufacturer)
  8. Published studyPubMed Central
    Sikirić P et al. Stable gastric pentadecapeptide BPC 157 — a review of the rodent literature
  9. Published studyPubMed Central
    Thymosin beta-4 (RGN-259) phase 3 in neurotrophic keratopathy
  10. Published studyAnnals of the New York Academy of Sciences 2010;1194:223–9· 2010-04
    Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta 4 in healthy volunteers
  11. Published studyDrug Testing and Analysis 2012;4(9):733–8· 2012-09
    Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500